UNLABELLED A novel, facile procedure for efficient coupling of high doses of (131)I to monoclonal antibodies (MAbs) was developed with minimal chemical and radiation damage. METHODS To diminish the radiation and chemical burden during labeling, iodination was performed in a large reaction volume and by temporarily coating the MAb with a minimal amount of IODO-GEN. The MAb was coated by inject...

Maternal attachment is known to be associated with children’s behavioral adjustment problems. Behavioural problems that emerge during childhood often persist into adolescence and are various negative outcomes. Therefore, this study aims determine the relationship between maternal among children in Selangor, Malaysia. The specific objectives demographic factors, adjustment. It also differences m...

PURPOSE A multicenter, randomized study was undertaken to estimate the single agent activity of Tositumomab and to determine the contribution of radioisotope-labeling with (131)I to activity and toxicity by comparing treatment outcomes for Tositumomab and Iodine I 131 Tositumomab (BEXXAR) to an equivalent total dose of unlabeled Tositumomab. EXPERIMENTAL DESIGN Seventy-eight patients with ref...

Objectives: I-131 is a widely used radiopharmaceutical for the management of patients with differentiated thyroid carcinoma (DTC). It is the main agent for the ablation of residual thyroid tissue and the treatment of recurrent or metastatic DTC. However, diagnostic doses of I-131 may cause some form of cell damage “stunning” which reduce subsequent uptake of the therapeutic dose of I-131. In co...

Iodine-131-labeled anti-CD45 antibody has been added to conventional hematopoietic stem cell transplant preparative regimens to deliver targeted radiation to hematopoietic tissues, with the goal of decreasing relapse rates without increasing toxicity. However, higher radiation doses could be delivered to leukemia cells by antibody if the systemic therapy were decreased or eliminated. To examine...

UNLABELLED Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I. The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form of cell damage from the diagnostic dosage of the radionuclide. Stunning could pote...

Clinical and Molecular Epidemiology of Escherichia coli Sequence Type 131 (ST131) 1 among Hospitalized Patients Colonized Intestinally with Fluoroquinolone-Resistant E. coli 2 3 Jennifer H. Han, MD, MSCE#; Brian Johnston, BS; Irving Nachamkin, DrPH, MPH; Pam 4 Tolomeo, MPH; Warren B. Bilker, PhD; Xiangqun Mao, PhD; Connie Clabots, MT; 5 Ebbing Lautenbach, MD, MPH, MSCE*; and James R. Johnson, M...

this study was done in research institute of nuclear medicine from 1988-1992 for evaluation of the value of serum thyroglobulin level in comparison with 1-131 whole body scan (1-131 wbs) in patients with differentiated thyroid carcinoma. 204 patients who had total or near total thyroidectomy treated with 1-131 were evaluated in this study. out of 204 patients 136 did not have regional or distan...

BACKGROUND Ablative radioiodine-131 ((131)I) therapy is used in the standart treatment procedure of thyroid carcinoma and procedures using (131)I represent the majority of Nuclear Medicine therapeutic procedures. The principal route of (131)I excretion after the administration of (131)I is the urine. Amifostine is an organic thiophosphate ester prodrug and the kidney concentrations of the activ...